- Correction
- Open access
- Published:
Correction: Cancer organoid-based diagnosis reactivity prediction (CODRP) index-based anticancer drug sensitivity test in ALK-rearrangement positive non-small cell lung cancer (NSCLC)
Journal of Experimental & Clinical Cancer Research volume 42, Article number: 332 (2023)
The Original Article was published on 22 November 2023
Correction: J Exp Clin Cancer Res 42, 309 (2023)
Following publication of the original article [1], authors would like to correct the Funding section of their article.
The sentence currently reads:
This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. 2019M3A9H2032425). This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (No. 2020R1I1A306655012). This work was supported by the Ministry of Science and ICT, (Project Number: (2022) ERIC07_1_1) and Commercialization Promotion Agency for R&D Outcomes (COMPA).
The sentence should read:
This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. 2019M3A9H2032425). This research was supported by the Commercialization Promotion Agency for R&D Outcomes(COMPA) funded by the Ministry of Science and ICT(MSIT) (project number: RS_2023-00259649, No. 1,711,196,063).This work was supported by the Korea Medical Device Development Fund grant funded by the Korea government (the Ministry of Science and ICT; the Ministry of Trade, Industry and Energy; the Ministry of Health & Welfare; and the Ministry of Food and Drug Safety) (project number: RS_2023-00255627).
The correction does not affect the overall result or conclusion of the article. The original article has been corrected.
References
Lee SY, Cho HJ, Choi J, et al. Cancer organoid-based diagnosis reactivity prediction (CODRP) index-based anticancer drug sensitivity test in ALK-rearrangement positive non-small cell Lung cancer (NSCLC). J Exp Clin Cancer Res. 2023;42:309. https://doi.org/10.1186/s13046-023-02899-4.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1186/s13046-023-02899-4.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Lee, SY., Cho, H.J., Choi, J. et al. Correction: Cancer organoid-based diagnosis reactivity prediction (CODRP) index-based anticancer drug sensitivity test in ALK-rearrangement positive non-small cell lung cancer (NSCLC). J Exp Clin Cancer Res 42, 332 (2023). https://doi.org/10.1186/s13046-023-02919-3
Published:
DOI: https://doi.org/10.1186/s13046-023-02919-3